Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Lilly Reports Fourth-Quarter and Full-Year 2008 Results
February 14th, 2009
Q4 Sales Essentially Flat, While Full-Year 2008 Sales Grew 9% -- 2008 Worldwide Sales Top $20 Billion; Animal Health Sales Top $1 Billion -- 8 Products Each Exceed $1 Billion in Annual Sales -- Gross Margin Improvements Continue -- Company Reports Q4 Loss of $3.31 per share Resulting From ImClone Acquisition; Excluding Charges, Q4 Non-GAAP EPS Rises 19% to $1.07 -- Full-Year 2008 Results Include Loss of $1.89 per share on a Reported Basis, or Non-GAAP EPS of $4.02 -- 2009 EPS Guidance Range Reconfirmed at $4.00 to $4.25. Eli Lilly and Company (NYSE:LLY) announced financial results for the fourth quarter and full year of...
Source: Law & Health Weekly (2009-02-14)
|
